EE200200211A - Bitsüklilised aminohapped kui farmatseutilised toimeained - Google Patents

Bitsüklilised aminohapped kui farmatseutilised toimeained

Info

Publication number
EE200200211A
EE200200211A EEP200200211A EEP200200211A EE200200211A EE 200200211 A EE200200211 A EE 200200211A EE P200200211 A EEP200200211 A EE P200200211A EE P200200211 A EEP200200211 A EE P200200211A EE 200200211 A EE200200211 A EE 200200211A
Authority
EE
Estonia
Prior art keywords
amino acids
active ingredients
pharmaceutical active
bicyclic amino
bicyclic
Prior art date
Application number
EEP200200211A
Other languages
English (en)
Estonian (et)
Inventor
Stephen Bryans Justin
Clive Blakemore David
Osborne Simon
Receveur Jean-Marie
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE200200211A publication Critical patent/EE200200211A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
EEP200200211A 1999-10-20 2000-10-17 Bitsüklilised aminohapped kui farmatseutilised toimeained EE200200211A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20
PCT/US2000/028687 WO2001028978A1 (en) 1999-10-20 2000-10-17 Bicyclic amino acids as pharmaceutical agents

Publications (1)

Publication Number Publication Date
EE200200211A true EE200200211A (et) 2003-06-16

Family

ID=22578159

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200211A EE200200211A (et) 1999-10-20 2000-10-17 Bitsüklilised aminohapped kui farmatseutilised toimeained

Country Status (50)

Country Link
US (2) US6689906B1 (enrdf_load_stackoverflow)
EP (2) EP1226110B1 (enrdf_load_stackoverflow)
JP (2) JP3632191B2 (enrdf_load_stackoverflow)
KR (2) KR100566462B1 (enrdf_load_stackoverflow)
CN (1) CN1165518C (enrdf_load_stackoverflow)
AP (2) AP2004003186A0 (enrdf_load_stackoverflow)
AR (2) AR026087A1 (enrdf_load_stackoverflow)
AT (2) ATE293590T1 (enrdf_load_stackoverflow)
AU (2) AU778871B2 (enrdf_load_stackoverflow)
BG (2) BG108860A (enrdf_load_stackoverflow)
BR (1) BR0014972B1 (enrdf_load_stackoverflow)
CA (1) CA2386297C (enrdf_load_stackoverflow)
CO (1) CO5280060A1 (enrdf_load_stackoverflow)
CR (1) CR6620A (enrdf_load_stackoverflow)
CU (1) CU23112A3 (enrdf_load_stackoverflow)
CZ (1) CZ295960B6 (enrdf_load_stackoverflow)
DE (2) DE60034157T2 (enrdf_load_stackoverflow)
DO (1) DOP2000000083A (enrdf_load_stackoverflow)
DZ (1) DZ3197A1 (enrdf_load_stackoverflow)
EA (1) EA005206B1 (enrdf_load_stackoverflow)
EC (1) ECSP045393A (enrdf_load_stackoverflow)
EE (1) EE200200211A (enrdf_load_stackoverflow)
ES (2) ES2237464T3 (enrdf_load_stackoverflow)
GE (1) GEP20043297B (enrdf_load_stackoverflow)
GT (2) GT200000183A (enrdf_load_stackoverflow)
HK (1) HK1049826B (enrdf_load_stackoverflow)
HN (1) HN2000000224A (enrdf_load_stackoverflow)
HR (2) HRP20020428B1 (enrdf_load_stackoverflow)
HU (1) HUP0203325A3 (enrdf_load_stackoverflow)
IL (3) IL164060A0 (enrdf_load_stackoverflow)
IS (2) IS6348A (enrdf_load_stackoverflow)
MA (1) MA26842A1 (enrdf_load_stackoverflow)
MX (1) MXPA02003229A (enrdf_load_stackoverflow)
MY (1) MY127678A (enrdf_load_stackoverflow)
NO (2) NO20021780L (enrdf_load_stackoverflow)
NZ (1) NZ517961A (enrdf_load_stackoverflow)
OA (1) OA12070A (enrdf_load_stackoverflow)
PA (1) PA8505201A1 (enrdf_load_stackoverflow)
PE (1) PE20010740A1 (enrdf_load_stackoverflow)
PL (1) PL354607A1 (enrdf_load_stackoverflow)
PT (1) PT1226110E (enrdf_load_stackoverflow)
SI (1) SI1226110T1 (enrdf_load_stackoverflow)
SK (1) SK5232002A3 (enrdf_load_stackoverflow)
SV (1) SV2001000188A (enrdf_load_stackoverflow)
TR (2) TR200201094T2 (enrdf_load_stackoverflow)
TW (2) TWI225855B (enrdf_load_stackoverflow)
UA (1) UA72931C2 (enrdf_load_stackoverflow)
WO (1) WO2001028978A1 (enrdf_load_stackoverflow)
YU (2) YU29302A (enrdf_load_stackoverflow)
ZA (1) ZA200202543B (enrdf_load_stackoverflow)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
KR100785182B1 (ko) * 2000-06-26 2007-12-11 워너-램버트 캄파니 엘엘씨 수면 장애를 위한 가바펜틴 유사체
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
SK12822003A3 (sk) 2001-04-19 2004-04-06 Warner - Lambert Company Llc Fúzne bicyklické alebo tricyklické aminokyseliny
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
KR100926921B1 (ko) * 2001-06-11 2009-11-17 제노포트 인코포레이티드 Ｇａｂａ 유사체의 프로드러그, 이의 조성물 및 용도
CN1625393A (zh) 2002-01-31 2005-06-08 沃纳-兰伯特公司 治疗耳鸣的α2δ配体
EP1480639A1 (en) * 2002-02-22 2004-12-01 Warner-Lambert Company LLC Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
JP2005534678A (ja) * 2002-06-27 2005-11-17 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 注意欠陥多動性障害の治療方法
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
CA2494811A1 (en) * 2002-08-15 2004-02-26 Pfizer Inc. Therapeutic use of fused bicyclic or tricyclic amino acids
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
WO2004052360A1 (en) 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
MXPA05006320A (es) 2002-12-13 2005-08-26 Warner Lambert Co Derivados de pregabalina para el tratamiento de fibromialgia y otros trastornos.
NZ539972A (en) 2002-12-13 2008-05-30 Warner Lambert Co Alpha-2-delta ligand to treat lower urinary tract symptoms
DE602004024317D1 (de) 2003-09-12 2010-01-07 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
CA2673545A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
BR122013020635A2 (pt) 2007-09-28 2019-08-06 Daiichi Sankyo Company, Limited Composto
BRPI1013482B8 (pt) * 2009-03-26 2021-05-25 Daiichi Sankyo Co Ltd método para produzir um composto
BR112013031360B1 (pt) 2011-06-08 2022-01-25 Daiichi Sankyo Company, Limited Método para produzir um composto
CA2838651C (en) 2011-06-08 2016-05-17 Daiichi Sankyo Company, Limited Method for producing bicyclic compound via claisen rearrangement
JP6017451B2 (ja) 2011-12-15 2016-11-02 第一三共株式会社 不斉触媒を用いる二環性化合物の光学分割方法
WO2013154066A1 (ja) 2012-04-10 2013-10-17 第一三共株式会社 酵素を用いる二環性化合物の光学分割方法
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN113045410A (zh) * 2021-03-29 2021-06-29 华东理工大学 一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) * 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DK1032555T3 (da) 1997-10-27 2006-07-17 Warner Lambert Co Cykliske aminosyrer og derivater deraf, som er anvendelige som lægemidler

Also Published As

Publication number Publication date
IL149143A0 (en) 2002-11-10
AR026087A1 (es) 2002-12-26
EP1226110B1 (en) 2005-04-20
CN1382118A (zh) 2002-11-27
JP2005036009A (ja) 2005-02-10
EA005206B1 (ru) 2004-12-30
CA2386297C (en) 2010-02-09
PL354607A1 (en) 2004-01-26
CR6620A (es) 2004-02-02
HRP20020428A2 (en) 2005-02-28
DE60019628D1 (de) 2005-05-25
EA200200293A1 (ru) 2002-10-31
TW200505824A (en) 2005-02-16
US20040152779A1 (en) 2004-08-05
BR0014972B1 (pt) 2011-09-06
JP2003512348A (ja) 2003-04-02
EP1506955B1 (en) 2007-03-28
BG108860A (en) 2006-03-31
KR20020040900A (ko) 2002-05-30
OA12070A (en) 2003-11-10
PA8505201A1 (es) 2002-08-29
CZ20021310A3 (cs) 2003-05-14
AR045456A2 (es) 2005-10-26
BR0014972A (pt) 2002-07-16
ES2237464T3 (es) 2005-08-01
AP2004003186A0 (en) 2004-12-31
TR200201094T2 (tr) 2002-09-23
SV2001000188A (es) 2001-09-07
HUP0203325A3 (en) 2003-12-29
TWI225855B (en) 2005-01-01
BG106719A (bg) 2003-02-28
NO20021780D0 (no) 2002-04-16
HRP20040709A2 (en) 2004-12-31
JP3744928B2 (ja) 2006-02-15
ES2282785T3 (es) 2007-10-16
TR200500221T2 (tr) 2005-03-21
ECSP045393A (es) 2004-10-23
MY127678A (en) 2006-12-29
AU2005201268A1 (en) 2005-04-21
UA72931C2 (uk) 2005-05-16
HK1049826B (zh) 2005-02-25
NZ517961A (en) 2002-12-20
DE60019628T2 (de) 2006-01-19
HK1049826A1 (en) 2003-05-30
HUP0203325A2 (hu) 2003-02-28
PE20010740A1 (es) 2001-07-27
IS6348A (is) 2002-04-17
CO5280060A1 (es) 2003-05-30
NO20043663L (no) 2002-04-16
US6835751B2 (en) 2004-12-28
CA2386297A1 (en) 2001-04-26
NO20021780L (no) 2002-04-16
DE60034157T2 (de) 2007-12-13
CZ295960B6 (cs) 2005-12-14
KR20060013701A (ko) 2006-02-13
CN1165518C (zh) 2004-09-08
SI1226110T1 (en) 2005-08-31
GEP20043297B (en) 2004-01-12
GT200000183A (es) 2000-10-19
MA26842A1 (fr) 2004-12-20
EP1506955A1 (en) 2005-02-16
WO2001028978A1 (en) 2001-04-26
SK5232002A3 (en) 2003-07-01
YU29302A (sh) 2005-06-10
AU1092001A (en) 2001-04-30
US6689906B1 (en) 2004-02-10
DE60034157D1 (de) 2007-05-10
MXPA02003229A (es) 2002-09-30
AP2002002517A0 (en) 2002-06-30
KR100593349B1 (ko) 2006-06-26
CU23112A3 (es) 2006-02-27
YU73004A (sh) 2005-11-28
GT200000183AA (es) 2005-06-17
DZ3197A1 (fr) 2001-04-26
PT1226110E (pt) 2005-07-29
DOP2000000083A (es) 2002-03-30
AU778871B2 (en) 2004-12-23
IS7497A (is) 2004-10-08
IL164060A0 (en) 2005-12-18
HN2000000224A (es) 2001-04-11
KR100566462B1 (ko) 2006-03-31
ATE293590T1 (de) 2005-05-15
JP3632191B2 (ja) 2005-03-23
ZA200202543B (en) 2003-09-23
ATE358116T1 (de) 2007-04-15
IL149143A (en) 2007-02-11
EP1226110A1 (en) 2002-07-31
HRP20020428B1 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
EE200200211A (et) Bitsüklilised aminohapped kui farmatseutilised toimeained
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
EP1233756A4 (en) SOLID EXCIPIENTS FOR IMPROVED ADMINISTRATION OF ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS
PL351526A1 (en) Pharmaceutical formulation comprising amoxycillin
NO20015175D0 (no) Farmasöytisk sammensetning
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
EE04418B1 (et) Moksifloksatsiini farmatseutiline preparaat
GB0012850D0 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
DK0941075T3 (da) Smagsmaskerende farmaceutisk doseringsform med hurtig frigivelse
DK1183026T3 (da) Forbedrede farmaceutiske formuleringer omfattende ritonavir
HUP0102369A3 (en) Amino acid derivatives and drugs containing the same as the active ingredient
EP1311239A4 (en) ORAL PEPTIDE ADMINISTRATION
HUP0203226A3 (en) Pharmaceutical composition comprising benzamide derivative as active ingredient
FI4488U1 (fi) Farmaseuttinen koostumus
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20004816D0 (no) Ny farmasøytisk formulering
NO20021036D0 (no) Farmasöytisk preparat
HU0402095D0 (en) Bicyclic amino acids as pharmaceutically active ingredients
SE9901967D0 (sv) New solid dosage formulation
SI1155014T1 (en) New benzimidazole compounds for use as active therapeutic substances, process for the preparation of these compoudns and pharmaceutical compositions comprising them